RT Journal Article
SR Electronic
T1 Vulnerability and burden of all-cause mortality associated with particulate air pollution increased during COVID-19 pandemic: a nationwide observed study in Italy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.02.20206052
DO 10.1101/2020.10.02.20206052
A1 Tingting Ye
A1 Rongbin Xu
A1 Wenhua Yu
A1 Zhaoyue Chen
A1 Yuming Guo
A1 Shanshan Li
YR 2020
UL http://medrxiv.org/content/early/2020/10/06/2020.10.02.20206052.abstract
AB Background Limited evidence is available on the health effects of particulate matter (i.e. PM2.5, particulate matter with an aerodynamic diameter < 2.5μm; PM10, < 10μm; PM2.5-10, 2.5-10μm) during the pandemic of COVID-19 in Italy.Objectives To examine the associations between all-cause mortality and daily PM2.5, PM2.5-10, and PM10 in the pandemic period, and compare them to the normal periods (2015-2019) in Italy.Methods We collected daily data regarding all-cause (stratified by age and gender), and PM2.5, PM2.5-10, and PM10 for 107 Italian provinces from 1, January 2015 to 31, May 2020. A time-stratified case-cross design with the distributed lag non-linear model was used to examine the association between PM and all-cause mortality during the first three months of the COVID-19 outbreak (March to May in 2020) and the same months in 2015-2019. We also compared the counts and fractions of death attributable to PM in two periods.Results Overall, Italy saw an increase in daily death counts while slight decreases in PM concentrations in 2020 pandemic period compared to same months of 2015-2019. Mortality effects were significant in lag 0-3 days for PM2.5, lag 0-2 for PM10, and lag 0-1 for PM2.5-10. Each 10 µg/m3 increase in PM was associated much higher increase in daily all-cause mortality during 2020 pandemic period compared to the same months during 2015-2019 [increased mortality rate: 7.24 % (95%CI: 4.84%, 9.70%) versus 1.69% (95%CI: 1.12%, 2.25%) for PM2.5; 3.45 % (95%C: 2.58%, 4.34%) versus 1.11% (95%CI: 0.79%, 1.42%) for PM10, 4.25% (95%CI: 2.99%, 5.52%) versus 1.76% (95%CI: 1.14%, 2.38%) for PM2.5-10]. The counts and fractions of deaths attributable to PM were higher in 2020 than the normal periods for PM2.5 (attributable death counts: 20,062 in 2020 versus 3,927 per year in 2015-2019; attributable fractions: 10.2% versus 2.4%), PM10 (15,112 versus 3,999; 7.7% versus 2.5%), and PM2.5-10 (7,193 versus 2303; 3.7% versus 1.4%).Conclusions COVID-19 pandemic increased the vulnerability and excess cases of all-cause mortality associated with short-term exposure to PM2.5, PM2.5-10 and PM10 in Italy, despite a decline in air pollution level. This suggests using historical PM-mortality association to calculate health benefits associated with reduction in PMs has big uncertainties.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: No specific funding for this study. TY, and RX were supported by China Scholarship Council funds (number 201906320051 for TY and 201806010405 for RX); SL by an Early Career Fellowship of the Australian National Health and Medical Research Council (number APP1109193); and YG by Career Development Fellowships of the Australian National Health and Medical Research Council (numbers APP1107107 and APP1163693)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Monash University approved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOriginal data are open sources.